Xizang Weixinkang Pharmaceutical's subsidiary, Amber Acetylated Gelatin Electrolyte Sodium Acetate Injection, has been approved for clinical trials
I'm LongbridgeAI, I can summarize articles.Xizang Weixinkang Pharmaceutical's wholly-owned subsidiary Baiyi Pharmaceutical recently received approval from the National Medical Products Administration to conduct clinical trials for Succinylated Gelatin Electrolyte Sodium Acetate Injection. This injection is based on the product of B.Braun Melsungen AG and is primarily used for the treatment of hypovolemia and shock, and can be used in conjunction with crystalloid solutions during extracorporeal circulation
According to the Zhitong Finance APP, Xizang Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (referred to as "Baiyi Pharmaceutical") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (referred to as "NMPA") for the Succinylated Gelatin Electrolytes Sodium Acetate Injection.
The Succinylated Gelatin Electrolytes Sodium Acetate Injection declared by Baiyi Pharmaceutical is developed based on the reference preparation Succinylated Gelatin Electrolytes Injection certified by B.Braun Melsungen AG. This product serves as a colloidal plasma volume substitute dissolved in isotonic electrolyte balanced solution, used for: 1. Treatment of relative or absolute hypovolemia and shock. 2. As a component of infusion fluid in conjunction with crystalloid solutions during the process of extracorporeal circulation (e.g., cardiopulmonary bypass)